P662 A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use
Mueller, S.(1);Khalid, M.(2);Patel, H.(2);Wilke, T.(3);Dittmar, A.(4);
(1)Ingress-Health HWM GmbH, RWE and Evidence Synthesis department, Wismar, Germany;(2)Galapagos NV, Real World Data- Outcomes Research and Epidemiology, Mechelen, Belgium;(3)Ingress-Health HWM GmbH, RWE and Evidence Synthesis, Wismar, Germany;(4)IPAM- eV, RWE and Evidence Synthesis department, Wismar, Germany
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires continuous medical treatment. Current epidemiological data about UC in Germany are lacking, and in particular, it is unknown how many patients are treated with advanced therapies.
This study aimed to investigate the prevalence and incidence of UC in Germany and describe the frequency of advanced therapy use in this population.
We used claims data from a regional German sickness fund (AOK PLUS). Continuously insured persons from 01/01/2015 until 31/12/2019 or death with at least 2 outpatient diagnoses documented by a specialist in 2 quarters within 12 months or one inpatient diagnosis (ICD-10: K51.-) were defined to be UC prevalent. Patients were defined to be incident in 2019 if the respective selection criteria could be observed in 2019, but no UC diagnosis was documented in the previous 4 years.
Age- and gender-standardized point prevalence was calculated on 01/01/2019, cumulative incidence was evaluated for the year 2019. Standardization was based on the age/gender distribution within the entire population of the German statutory insurance (KM-6 statistic), which covers about 90% of the whole German population.
Main characteristics and comorbidity status were assessed at the index date based on diagnoses documented in the 12-month pre-index period (index: 01/01/2019 or date of incident diagnosis in 2019).
The proportion of prevalent patients receiving advanced therapies (infliximab, adalimumab, golimumab, vedolizumab, tofacitinib) was evaluated in 2019, considering both out- and inpatient treatments.
The standardized incidence in 2019 was 0.36 cases/1,000 persons. Incident patients were, on average, 59.7 years old (SD: 21.6; 95% CI: 58.2-61.1), and 56.1% were females. The mean Charlson Comorbidity Index (CCI) was 2.7 (SD: 3.1; 95% CI: 2.5-2.9).
The standardized prevalence at 01/01/2019 was 5.29 cases/1,000 persons. In 2019, 12,736 prevalent patients were observed (12,510.8 person-years), with 56.2% of the patients being female. The mean age was 60.6 years (SD: 18.8; 95% CI: 60.2-60.9), and the mean CCI was 2.3 (SD: 2.8; 95% CI: 2.2-2.3). 827 patients (6.5%) were treated with advanced therapy in 2019. These patients were considerably younger (44.9 (95% CI: 43.9-46.0) versus 61.7 years (95% CI: 61.3-62.0)) and less comorbid (CCI: 1.2 (95% CI: 1.0-1.3) vs. 2.4 (95% CI: 2.3-2.4)) than patients who have not been treated with an advanced therapy.
Our analysis showed a considerable UC incidence and a high disease burden in Germany, with a prevalence surpassing 0.5%. Advanced therapies were prescribed only in a minority of UC patients, who were generally younger and less comorbid.